Q-omics provides the consensus-scored RTL8A profile across patient tissues and cancer cell-line models. RTL8A expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, RTL8A is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, RTL8A RNA expression shows 17,761 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BRCA, KIRC, and TGCT as cancer lineages where RTL8A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RTL8A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RTL8A survival associations across molecular data types. RTL8A RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RTL8A RNA expression–survival associations across cancer types. High RTL8A expression shows unfavorable associations in BRCA, LIHC, KICH, COAD and ACC, but favorable associations in UVM. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for RTL8A RNA expression.
This table summarizes RTL8A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for RTL8A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RTL8A shows higher tumor expression in KIRC, KIRP, HNSC, LUSC, CHOL and LIHC. The KIRC box plot shows higher RTL8A RNA expression in tumor versus normal tissue (log2 FC = +0.846, t-test p < 0.001).
This table shows molecular features associated with RTL8A in patient tissues and cancer cell lines. In patient samples, RTL8A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, RTL8A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BONE and BLOOD_Lymphoma.
